A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 [telcagepant] With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura

Trial Profile

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 [telcagepant] With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Telcagepant (Primary) ; Zolmitriptan
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 27 Jun 2008 Results presented at American Headache Society annual meeting 2008.
    • 23 Oct 2007 Status changed from in progress to completed.
    • 17 Aug 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top